CCALDCouncil of Connecticut Academic Library Directors
References in periodicals archive ?
bluebird bio's CCALD product program has the potential to halt the progression of CCALD by providing a functional ABCD1 gene to the patient's own stem cells.
The presentation will include updates on the launch of the company's pivotal CCALD clinical trial, as well as patient data updates and enrollment of the ongoing beta-thalassemia/sickle cell disease trial.
We are committed to building a world-class company in gene therapy led by outstanding people as we move aggressively forward with multiple clinical studies, including our ongoing clinical trials for the development of LentiGlobin for beta-thalassemia and our product for CCALD.